Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.62 |
| ▸ | ITGAV | P06756 | 16/20 | 0.62 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.62 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.59 |
| ▸ | ITGB5 | P18084 | 9/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30116037 | 0.96 | ITGB3 (0.61) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL13481946 | 0.90 | ITGB3 (0.50) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL13481608 | 0.90 | ITGB3 (0.50) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL31294830 | 0.83 | ITGB3 (0.80) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL29366713 | 0.82 | ITGB3 (0.74) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL17364341 | 0.82 | ITGB3 (0.74) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL14075702 | 0.81 | MC4R (0.44) | ITGB3ITGAVITGA5ITGB1ITGB5 | |
| SCHEMBL13465281 | 0.81 | ITGB3 (0.49) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL18080800 | 0.81 | ITGB3 (0.49) | ITGB3ITGAVITGA5ITGB1ITGA2B | |
| SCHEMBL13481610 | 0.81 | ITGB3 (0.49) | ITGB3ITGAVITGA5ITGB1ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254085-A1 | CHELATORS FOR RADIOMETALS AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-08-01 | — | — | US | claimed |
| EP-4334290-A1 | CHELATORS FOR RADIOMETALS AND METHODS OF MAKING AND USING SAME | The University of British Columbia (CA) | 2024-03-13 | — | — | EP | claimed |
| US-20230348378-A1 | SMALL MOLECULE ALBUMIN BINDERS | OREGON HEALTH & SCIENCE UNIVERSITY | 2023-11-02 | — | — | US | claimed |
| EP-4110768-A1 | CHELATOR COMPOSITIONS FOR RADIOMETALS AND METHODS OF USING SAME | Triumf Inc. (CA) | 2023-01-04 | — | — | EP | claimed |
| WO-2022232943-A1 | CHELATORS FOR RADIOMETALS AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-11-10 | — | — | WO | claimed |
| WO-2022040607-A1 | SMALL MOLECULE ALBUMIN BINDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-02-24 | — | — | WO | claimed |
| EP-3634474-B1 | TARGETING MODULES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS AND USE IN THE TREATMENT OF CANCER INFECTIONS AND AUTOIMMUNE DISORDERS | AVENCELL EUROPE GMBH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12605447-B2 | Stable formulations for radionuclide complexes | ITM SOLUCIN GMBH (DE) | 2026-04-21 | — | — | US | disclosed |
| US-12562258-B2 | Methods and systems for assessing treatment of a disease based on lesion features | AIQ GLOBAL INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260027239-A1 | cRGD -CONJUGATED IMAGING AGENT | CURADEL SURGICAL INNOVATIONS, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| US-12514939-B2 | Stable radiopharmaceutical compositions and uses thereof | ALPHA-9 ONCOLOGY, INC. (CA) | 2026-01-06 | — | — | US | disclosed |
| US-20250255993-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ALPHA-9 ONCOLOGY INC. (CA) | 2025-08-14 | — | — | US | disclosed |
| EP-4585609-A1 | RGD DIMER COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Yantai Lannacheng Biotechnology Co., Ltd. (CN) | 2025-07-16 | — | — | EP | disclosed |
| US-20220133919-A1 | ONE STEP 64Cu-BaBaSar-RGD2 PRODUCTION METHOD | UNIV SOUTHERN CALIFORNIA (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220119488-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN ALPHA-V-BETA-3 | Bicyclerd Limited (GB) | 2022-04-21 | — | — | US | disclosed |
| EP-3965751-A1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM Isotope Technologies Munich SE (DE) | 2022-03-16 | — | — | EP | disclosed |
| EP-3965892-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN ALPHA V BETA 3 | Bicyclerd Limited (GB) | 2022-03-16 | — | — | EP | disclosed |
| US-20220064221-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN ALPHA-V-BETA-3 | BICYCLETX LIMITED (GB) | 2022-03-03 | — | — | US | disclosed |
| CN-114126654-A | Para-aminohippuric acid (PAH) as a kidney protective substance | 同位素技术慕尼黑有限公司 | 2022-03-01 | — | — | CN | disclosed |
| WO-2022040607-A1 | SMALL MOLECULE ALBUMIN BINDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605447-B2 | Stable formulations for radionuclide complexes | EPOR, CD47, PRCP | ITGB3 1415/4885ITGAV 861/4885ITGA5 1268/4885 |
| US-20220119488-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN ALPHA-V-BETA-3 | ITGB3, ITGAV, ITGB2 | ITGB3 1/4885ITGAV 2/4885ITGA5 15/4885 |
| US-20220064221-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN ALPHA-V-BETA-3 | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGAV 2/4885ITGA5 11/4885 |
| US-20250255993-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | RCN1, RABL6, QPCT | ITGB3 2423/4885ITGAV 1694/4885ITGA5 2186/4885 |
| US-12562258-B2 | Methods and systems for assessing treatment of a disease based on lesion features | VHL, HRAS, MKI67 | ITGB3 2987/4885ITGAV 2071/4885ITGA5 4394/4885 |
| US-20260027239-A1 | cRGD -CONJUGATED IMAGING AGENT | ADGRF1, FZD7, RXFP3 | ITGB3 4/4885ITGAV 19/4885ITGA5 32/4885 |
| US-20230348378-A1 | SMALL MOLECULE ALBUMIN BINDERS | ALB, FABP1, FABP3 | ITGB3 1258/4885ITGAV 944/4885ITGA5 2649/4885 |
| US-20240254085-A1 | CHELATORS FOR RADIOMETALS AND METHODS OF MAKING AND USING SAME | RXFP3, SLC39A3, NR4A3 | ITGB3 582/4885ITGAV 2732/4885ITGA5 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.